News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,933 Results
Type
Article (41510)
Company Profile (259)
Press Release (664164)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (206324)
Career Advice (2037)
Deals (35726)
Drug Delivery (95)
Drug Development (81409)
Employer Resources (172)
FDA (16303)
Job Trends (15047)
News (348532)
Policy (32986)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2636)
Academic (1)
Accelerated approval (5)
Adcomms (20)
Allergies (83)
Alliances (50215)
ALS (86)
Alzheimer's disease (1381)
Antibody-drug conjugate (ADC) (112)
Approvals (16304)
Artificial intelligence (243)
Autoimmune disease (20)
Automation (15)
Bankruptcy (364)
Best Places to Work (11711)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (180)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (262)
Cancer (2091)
Cardiovascular disease (171)
Career advice (1703)
Career pathing (30)
CAR-T (143)
Cell therapy (404)
Cervical cancer (20)
Clinical research (66026)
Collaboration (801)
Compensation (508)
Complete response letters (19)
COVID-19 (2632)
CRISPR (38)
C-suite (225)
Cystic fibrosis (100)
Data (2055)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (257)
Diagnostics (6520)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (119)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86791)
Editorial (35)
Employer branding (21)
Employer resources (146)
Events (112713)
Executive appointments (697)
FDA (17489)
Featured Employer (48)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (727)
Gene editing (102)
Generative AI (19)
Gene therapy (287)
GLP-1 (709)
Government (4453)
Grass and pollen (4)
Guidances (51)
Healthcare (18949)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (110)
Indications (26)
Infectious disease (2775)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (91)
Interviews (315)
IPO (16565)
IRA (40)
Job creations (3750)
Job search strategy (1449)
Kidney cancer (9)
Labor market (36)
Layoffs (463)
Leadership (17)
Legal (8023)
Liver cancer (72)
Lung cancer (305)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (283)
MASH (63)
Medical device (13411)
Medtech (13416)
Mergers & acquisitions (19677)
Metabolic disorders (659)
Multiple sclerosis (75)
NASH (17)
Neurodegenerative disease (84)
Neuropsychiatric disorders (24)
Neuroscience (1886)
NextGen: Class of 2025 (6551)
Non-profit (4532)
Northern California (2536)
Now hiring (38)
Obesity (355)
Opinion (206)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (147)
Partnered (21)
Patents (222)
Patient recruitment (99)
Peanut (47)
People (57851)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20578)
Phase II (29053)
Phase III (21663)
Pipeline (1120)
Policy (130)
Postmarket research (2584)
Preclinical (8796)
Press Release (67)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (245)
Rare diseases (372)
Real estate (6119)
Recruiting (65)
Regulatory (22511)
Reports (46)
Research institute (2383)
Resumes & cover letters (350)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (126)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2188)
Special edition (14)
Spinal muscular atrophy (148)
Sponsored (31)
Startups (3618)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (28)
United States (22100)
Vaccines (672)
Venture capitalists (38)
Weight loss (231)
Women's health (34)
Worklife (15)
Date
Last 7 days (471)
Last 30 days (2203)
Last 365 days (32965)
2025 (9247)
2024 (35424)
2023 (40335)
2022 (51425)
2021 (56017)
2020 (54500)
2019 (46966)
2018 (35323)
2017 (32520)
2016 (31979)
2015 (38001)
2014 (31864)
2013 (26985)
2012 (29107)
2011 (29783)
2010 (27820)
Location
Africa (734)
Alabama (52)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (38566)
Australia (6316)
California (5794)
Canada (1949)
China (492)
Colorado (255)
Connecticut (262)
Delaware (134)
Europe (83065)
Florida (861)
Georgia (203)
Idaho (57)
Illinois (515)
India (25)
Indiana (301)
Iowa (9)
Japan (149)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (862)
Massachusetts (4341)
Michigan (215)
Minnesota (382)
Mississippi (2)
Missouri (83)
Montana (30)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1667)
New Mexico (29)
New York (1657)
North Carolina (954)
North Dakota (7)
Northern California (2536)
Ohio (198)
Oklahoma (14)
Oregon (33)
Pennsylvania (1307)
Puerto Rico (11)
Rhode Island (30)
South America (1126)
South Carolina (20)
South Dakota (1)
Southern California (2188)
Tennessee (99)
Texas (866)
Utah (173)
Virginia (135)
Washington D.C. (59)
Washington State (533)
West Virginia (3)
Wisconsin (51)
705,933 Results for "cdi laboratories inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
February 25, 2025
·
15 min read
Policy
Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView™ Monitoring System
Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration has granted 510 clearance for the CDI OneView Monitoring System.
May 28, 2024
·
3 min read
Press Releases
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
January 6, 2025
·
13 min read
Business
Barney E. Saunders Ph.D. has been appointed Chief Executive Officer of CDI Laboratories
CDI Laboratories Inc., the Seromics™ company, announced that Barney E. Saunders Ph.D. has been appointed Chief Executive Officer.
August 2, 2023
·
2 min read
Press Releases
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
January 9, 2025
·
6 min read
Drug Development
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Pharmaceuticals, Inc. today announced positive extended clinical cure (ECC) data for ibezapolstat (IBZ), its lead antibiotic candidate, from the Company’s recently completed Phase 2b clinical trial in patients with CDI.
January 29, 2024
·
13 min read
Drug Development
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Pharmaceuticals, Inc. today announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company’s recently completed Phase 2b clinical trial in patients with CDI.
January 17, 2024
·
14 min read
BioCapital
BroadOak Capital Partners Invests in CDI Laboratories to Expand and Scale Antibody Biomarker Discovery Platforms
CDI Laboratories, Inc announced that it has received a significant investment from BroadOak Capital Partners that will enable CDI Labs to meet increased demand for its HuProtTM proteome microarray autoantibody biomarker discovery product line and launch new phage display immunoprecipitation sequencing services.
January 9, 2023
·
2 min read
Press Releases
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
September 27, 2024
·
5 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
1 of 70,594
Next
